Katz A, Vlodavsky I, Davies M, Miao H Q, Ben-Sasson S A, Darmon D, Hurwitz H, Borgel H, Benezra M
Department of Oncology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
J Am Soc Nephrol. 1997 Nov;8(11):1688-97. doi: 10.1681/ASN.V8111688.
Proliferation of mesangial cells (MC) is a key feature in the pathogenesis of numerous renal diseases involving the glomerulus. Heparin, one of several compounds capable of suppressing MC proliferation, did not prove beneficial in the treatment of human glomerular diseases. In a search for a superior antiproliferative agent, a synthetic polyaromatic "heparin mimicking" compound (RG-13577, polymer of 4-hydroxyphenoxy acetic acid, M(r) approximately 5800), previously reported to inhibit the proliferation of vascular smooth muscle cells, was applied. RG-13577 exhibits approximately 1% of the anticoagulant activity of heparin and is nontoxic in animal experiments. Proliferation of primary rat MC was almost completely inhibited in the presence of 10 to 25 micrograms/ml RG-13577, and 50% inhibition was obtained at 1 to 5 micrograms/ml RG-13577. The cells resumed their normal growth rate after removal of RG-13577 from the culture medium. Under the same conditions, heparin exerted only a small inhibitors effect. RG-13577 inhibited signaling (i.e., tyrosine phosphorylation) and MC proliferation induced by both basic fibroblast growth factor and platelet-derived growth factor. RG-13577 binds to a naturally produced extracellular matrix, and the bound molecule retained its antiproliferative effect toward MC. 14C-Labeled RG-13577 also binds to cultured MC in a specific and saturable manner. Binding of 14C-RG-13577 was reduced by 80 to 90% in the presence of excess unlabeled RG-13577, apolipoprotein E, or lactoferrin, but there was no effect with heparin. Furthermore, the antiproliferative effect of RG-13577 was abolished in the presence of lactoferrin. It is proposed that compound RG-13577 inhibits MC proliferation through neutralization of growth-promoting factors, primarily heparin-binding growth factors, and possibly through binding to specific cell surface receptors, most likely the LDL receptor-related protein. RG-13577 and related polyanionic compounds may be applied to inhibit MC proliferation in glomerular diseases.
系膜细胞(MC)增殖是许多累及肾小球的肾脏疾病发病机制的关键特征。肝素是几种能够抑制MC增殖的化合物之一,但在治疗人类肾小球疾病方面并未显示出益处。为了寻找一种更有效的抗增殖剂,应用了一种合成的多芳族“肝素模拟”化合物(RG - 13577,4 - 羟基苯氧基乙酸聚合物,分子量约5800),该化合物先前已报道可抑制血管平滑肌细胞的增殖。RG - 13577的抗凝活性约为肝素的1%,并且在动物实验中无毒。在存在10至25微克/毫升RG - 13577的情况下,原代大鼠MC的增殖几乎完全被抑制,在1至5微克/毫升RG - 13577时可获得50%的抑制率。从培养基中去除RG - 13577后,细胞恢复其正常生长速率。在相同条件下,肝素仅发挥较小的抑制作用。RG - 13577抑制由碱性成纤维细胞生长因子和血小板衍生生长因子诱导的信号传导(即酪氨酸磷酸化)和MC增殖。RG - 13577与天然产生的细胞外基质结合,并且结合的分子对MC保留其抗增殖作用。14C标记的RG - 13577也以特异性和可饱和的方式与培养的MC结合。在存在过量未标记的RG - 13577、载脂蛋白E或乳铁蛋白的情况下,14C - RG - 13577的结合减少80%至90%,但肝素无此作用。此外,在乳铁蛋白存在的情况下,RG - 13577的抗增殖作用被消除。有人提出,化合物RG - 13577通过中和生长促进因子,主要是肝素结合生长因子来抑制MC增殖,并且可能通过与特定细胞表面受体结合,最有可能是低密度脂蛋白受体相关蛋白。RG - 13577和相关的聚阴离子化合物可用于抑制肾小球疾病中的MC增殖。